Regeneron Must Face Suit Over Covid Antibody Cocktail Technology

Regeneron Pharmaceuticals Inc. can’t shake allegations that it infringed a California biotechnology company’s patent with its Covid-19 “antibody cocktail,” a federal judge ruled.

Allele Biotechnology and Pharmaceuticals Inc. sued Regeneron for using its patented technology in developing its Covid-19 treatment without the company’s authorization. Regeneron moved last August to get the U.S. District Court for the Southern District of New York to drop the suit, claiming it was shielded from liability under a legal “safe harbor” for using a patented invention in relation to the development of drug information for the Food and Drug Administration.

On Wednesday, however, Judge Philip ...